CureVac N.V. (CVAC)
NASDAQ: CVAC · Real-Time Price · USD
2.490
-0.010 (-0.40%)
At close: Nov 20, 2024, 4:00 PM
2.610
+0.120 (4.82%)
After-hours: Nov 20, 2024, 4:38 PM EST
CureVac Employees
As of December 31, 2023, CureVac had 1,172 total employees, including 999 full-time and 173 part-time employees. The number of employees increased by 123 or 11.73% compared to the previous year.
Employees
1,172
Change (1Y)
123
Growth (1Y)
11.73%
Revenue / Employee
$60,210
Profits / Employee
-$254,547
Market Cap
558.54M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,172 | 123 | 11.73% |
Dec 31, 2022 | 1,049 | 165 | 18.67% |
Dec 31, 2021 | 884 | 330 | 59.57% |
Dec 31, 2020 | 554 | 100 | 22.03% |
Dec 31, 2019 | 454 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Varex Imaging | 2,400 |
Surmodics | 376 |
Simulations Plus | 197 |
AnaptysBio | 117 |
Annexon | 71 |
ABIVAX Société Anonyme | 61 |
Immunome | 55 |
Tectonic Therapeutic | 44 |
CVAC News
- 8 days ago - CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update - Accesswire
- 14 days ago - CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 - Accesswire
- 17 days ago - CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer - Accesswire
- 17 days ago - CureVac to Present at the 12th International mRNA Health Conference - Accesswire
- 24 days ago - CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Accesswire
- 6 weeks ago - Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents - Reuters
- 2 months ago - CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress - Accesswire